Background: In the setting of PCI for ULMCA disease, left anterior descending artery (LAD) is generally considered the main branch. However, whether the choice of LAD over LCX as main branch has a significant impact on clinical outcomes has not yet been ascertained. Methods: Between April 2002 and April 2006, a total of 2775 patients were included in the DELTA registry: 1,874 were treated with PCI versus 901 with CABG. Of the percutaneous group, we selected only those patients who had distal left main disease and complete information about stenting technique. After 1:1 propensity-score matching was performed, matched pairs of patients were selected and analyzed. Results: In total 276 patients were included in the analysis: in 138 cases the selected main branch was the LAD (LM-LAD) and in 138 cases was the LCX (LM-LCX). Clinical, angiographic and procedural characteristics in the matched groups were similar. Mean EuroSCORE and SyntaxSCORE in the LM-LAD and LM-LCX groups were 5.3AE3.2 vs 5.5AE3.6 (p¼ 0.34) and 29.7AE10.8 vs 28.9AE10 (p¼ 0.56). Two stent strategy was used in 57.2% vs. 53.6% of cases (p¼0.56). Incidence of adverse events at follow-up (median: 1098 days; IQR 396-1478) are reported in Table 1 . MACCEfree survival rate in the LM-LAD and LM-LCX groups at1478 days was 60.4 % vs 51.2% (p¼0.012). When stratified by stent strategy (1 vs 2 stent technique), the significant advantage of the LM-LAD subgroup in terms of death, TLR, TVR and MACCE was confirmed in patients who were treated with a 2 stent technique while no difference between groups was found when a single stent strategy was considered.
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Conclusions: In this series of matched patients with ULMCA disease, the choice of LAD over LCX as main branch was correlated with a significantly lower incidence of death, TLR, TVR and MACCE at long term FU. This advantage was substantial when a two stent strategy was considered. Background: Triple kissing balloon technique (triple-KBT) is a promising technique to treat the left main (LM) trifurcation lesions with both single-and two-stent techniques using drug-eluting stent (DES). However, the difference in clinical and angiographic outcomes after DES implantation with triple-KBT between single-and two-stent techniques was unknown. Methods: From April 2005 to October 2012, 72 patients underwent DES implantation with triple-KBT for LM trifurcation disease. We compared the clinical and angiographic outcomes between single-(45 patients) and two-stent groups (27 patients). Clinical outcomes were evaluated by all-cause death and target lesion revascularization (TLR). Follow-up angiography was scheduled at 8 months after procedure. Results: The angiographic success rate was 100%, and in-hospital death and coronary artery bypass grafting were nothing. Procedural and angiographic follow-up data are shown in the table. The two-stent group had more severe stenosis of side branches than the single-stent group. The restenosis rate was similar between the 2 groups. The median clinical follow-up duration was 797 days (interquartile range 595-977 days). The incidence of TLR at 1 year was significantly lower in the single-stent group than in the two-stent group (4.5% vs. 32.3%, p¼0.002), and the incidence of TLR was nothing since 1 year after procedure in both 2 groups.
Conclusions: Triple-KBT after DES implantation was a safe and feasible technique for LM trifurcation disease. Single-stent technique with triple-KBT was associated with more favorable clinical outcomes compared with two-stent technique. Background: The percutaneous treatment of coronary bifurcation lesions with stent implantation is associated with increased adverse clinical events and inferior angiographic outcomes, when compared with mid-vessel lesions. The Axxess stent is a dedicated, self-expanding, drug-eluting (Biolimus A9) bifurcation stent. The aim of the present registry is to evaluate the feasibility in terms of procedural technique and success, the efficacy in terms of MACCE (cardiac death, Q-wave-MI, non Q-wave-MI, TVR,TLR and stroke) and the safety in terms of stent thrombosis occurrence at 30 days, 6 and 12 months follow-up of a new bifurcation dedicated self-expandable biodegradable polymer BES. Methods: All consecutive patients referred to our cath-lab with de novo bifurcation lesions, in which we implanted bifurcation dedicated self-expandable biodegradable polymer stent, were included in our study. The choice of this stent has been left to the operator's discretion considering the coronary anatomy and lesions characteristics. The mean clinical follow-up was 3.9 months. Results: 59 pts were treated with 60 Axxess stents. True bifurcations were 69.4% according to the Medina classification. The mean angle was 52.9 AE10.7 . Predilatation was performed in 98.3% (89.8% with kissing balloon and 11.8% with rotablator) and postdilatation with kissing balloon in 55.9%. Additional stenting was implanted on PV distally to AXXESS in 52.5% pts; 30.5% in SB and 16.9% in both branches. The placement was scored as optimal in 81.3% . Procedural angio success was 100%. RVD was 3.1AE0.26 mm, pre-procedure MLD was 0.51AE0.39 mm, final in Axxess MLD was 3.12AE0.28 mm. 100% of patients received a clinical follow-up. The cumulative 30-days (100% pts) MACCE rate was 3.3% (1.6% non-Q-wave MI, 1.6% Q-wave MI, 1.6% TVR, 1.6% TLR) and one acute ST. At 6 (32.2%) and 12 months (27.1%) cumulative MACCE rate was 13.5% (1.6% non-Q-wave MI, 3.3% Q-wave MI, 5% TVR, 3.3% TLR and 3.3% STROKE). No sub-acute and LST were found. 
P O S T E R S

